Cafelkibart’s entry into phase 3 is of note to Coherus.
ApexOnco Front Page
Recent articles
The company is starting four new pivotal trials this year.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
But more detail is awaited, especially on toxicity.
